Gland Pharma shares in focus after subsidiary Cenexi gets 11 observations from French regulator

Gland Pharma shares will be in focus after its subsidiary Cenexi received 11 observations from France’s ANSM following a GMP inspection at its Fontenay facility. The company clarified that operations remain unaffected and a CAPA plan has been accepted. Gland Pharma shares have risen 16% in a month, though the stock is still down 43% over three years.